Compare UVSP & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVSP | ABUS |
|---|---|---|
| Founded | 1876 | 2005 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 983.8M | 848.8M |
| IPO Year | 1994 | 2008 |
| Metric | UVSP | ABUS |
|---|---|---|
| Price | $37.58 | $4.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $36.67 | $5.00 |
| AVG Volume (30 Days) | 157.8K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | 21.32 | ★ 55.26 |
| EPS | ★ 0.96 | 0.87 |
| Revenue | ★ $328,056,000.00 | $14,083,000.00 |
| Revenue This Year | $11.65 | N/A |
| Revenue Next Year | $4.77 | $239.71 |
| P/E Ratio | $39.70 | ★ $4.95 |
| Revenue Growth | 9.64 | ★ 128.21 |
| 52 Week Low | $27.91 | $3.04 |
| 52 Week High | $39.06 | $5.10 |
| Indicator | UVSP | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 51.81 | 45.31 |
| Support Level | $32.00 | $4.17 |
| Resistance Level | $37.72 | $4.62 |
| Average True Range (ATR) | 0.68 | 0.16 |
| MACD | -0.19 | -0.00 |
| Stochastic Oscillator | 19.66 | 46.23 |
Univest Financial Corp is engaged in domestic banking services for individuals, businesses, municipalities and non-profit organizations. The bank has three operating segments; Banking segment provides financial services including a full range of banking services such as deposit taking, loan origination, and servicing, mortgage banking, other general banking services, and equipment lease financing, Wealth Management segment offers investment advisory, financial planning, trust and brokerage services, and The Insurance segment includes a full-service insurance brokerage agency offering commercial property and casualty insurance, employee benefits solutions, personal insurance lines and human resources consulting. It generates majority of its revenue from the banking segment.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.